Key facts
- This page summarizes Francois Roger Michelon's Form 4 filing for ENDRA Life Sciences Inc. (NDRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Feb 2023, 19:30.
Francois Roger Michelon - 30 Jan 2023 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- NDRA
- Reported as of
- 30 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2023, 19:30:11 UTC
- Prior SEC filing
- 19 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francois R. Michelon by Mark Busch, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Francois Roger Michelon filed Form 4 for ENDRA Life Sciences Inc. (NDRA) on 01 Feb 2023.
Change
- Previous filing in this sequence was filed on 19 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NDRA
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +69,531
- Change %
- Price
- $0.000000
- Shares after
- 69,531
- Date
- 30 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,531
- Exercise price
- $4.02
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024.